Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 7/20 | 0.46 |
| ▸ | THRB | P10828 | 7/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517480 | 0.87 | THRA (0.49) | THRATHRBMTNR1AMTNR1BKDM4E | |
| SCHEMBL4518407 | 0.87 | MTNR1A (0.45) | THRATHRBMTNR1AMTNR1BKDM4E | |
| SCHEMBL3991336 | 0.79 | THRA (0.49) | THRATHRBKDM4EALDH1A1HPGD | |
| SCHEMBL6513910 | 0.73 | THRA (0.73) | THRATHRB | |
| SCHEMBL4513504 | 0.73 | PPARG (0.49) | THRATHRBMTNR1AMTNR1BKDM4E | |
| SCHEMBL3994062 | 0.72 | KDM4E (0.55) | THRATHRBKDM4EALDH1A1HPGD | |
| SCHEMBL4525261 | 0.71 | PPARG (0.43) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL4298483 | 0.70 | THRA (0.45) | THRATHRBALDH1A1 | |
| SCHEMBL6515221 | 0.69 | THRA (0.69) | THRATHRB | |
| SCHEMBL4527795 | 0.69 | THRB (0.52) | THRATHRBMTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233979-A1 | Indole Derivatives and Their Use as Thyroid Receptor Ligands | KARO BIO AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233979-A1 | Indole Derivatives and Their Use as Thyroid Receptor Ligands | KARO BIO AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233979-A1 | Indole Derivatives and Their Use as Thyroid Receptor Ligands | KARO BIO AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233979-A1 | Indole Derivatives and Their Use as Thyroid Receptor Ligands | TSHR, TRHR, THRA | THRA 3/4885THRB 4/4885MTNR1A 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.